{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:52:43Z","timestamp":1793303563425,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40273-025-01528-6","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:42:35Z","timestamp":1758638555000},"page":"1479-1494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-\u03b2-Lactamase (MBL)-Producing Enterobacterales in Italy"],"prefix":"10.1007","volume":"43","author":[{"given":"Marco","family":"Falcone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionn","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-3026","authenticated-orcid":false,"given":"Maria Alejandra","family":"Vidal Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9222-5295","authenticated-orcid":false,"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-6063","authenticated-orcid":false,"given":"Maria","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"10325","key":"1528_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"1528_CR2","unstructured":"O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016. https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf. Accessed May 2024."},{"key":"1528_CR3","doi-asserted-by":"publisher","first-page":"Doc05","DOI":"10.3205\/dgkh000290","volume":"12","author":"M Exner","year":"2017","unstructured":"Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, et al. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017;12:Doc05. https:\/\/doi.org\/10.3205\/dgkh000290.","journal-title":"GMS Hyg Infect Control"},{"key":"1528_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.127249","volume":"266","author":"J Ma","year":"2023","unstructured":"Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res. 2023;266: 127249. https:\/\/doi.org\/10.1016\/j.micres.2022.127249.","journal-title":"Microbiol Res"},{"issue":"2","key":"1528_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106528","volume":"59","author":"YL Lee","year":"2022","unstructured":"Lee YL, Chen HM, Hii IM, Hsueh PR. Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment. Int J Antimicrob Agents. 2022;59(2): 106528. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106528.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1528_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/cmr.00001-07","volume":"20","author":"AM Queenan","year":"2007","unstructured":"Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440\u201358. https:\/\/doi.org\/10.1128\/cmr.00001-07.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"1528_CR7","doi-asserted-by":"publisher","first-page":"298.e1","DOI":"10.1016\/j.cmi.2021.06.031","volume":"28","author":"M Falcone","year":"2022","unstructured":"Falcone M, Tiseo G, Galfo V, Giordano C, Leonildi A, Marciano E, et al. Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study. Clin Microbiol Infect. 2022;28(2):298.e1-7. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.031.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1528_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2012.06796.x","volume":"1277","author":"T Palzkill","year":"2013","unstructured":"Palzkill T. Metallo-\u03b2-lactamase structure and function. Ann N Y Acad Sci. 2013;1277(1):91\u2013104. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06796.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"1528_CR9","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/aac.00397-20","volume":"64","author":"SE Boyd","year":"2020","unstructured":"Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10):e00397-e420. https:\/\/doi.org\/10.1128\/aac.00397-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1528_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa011","volume":"7","author":"M Falcone","year":"2020","unstructured":"Falcone M, Tiseo G, Antonelli A, Giordano C, Di Pilato V, Bertolucci P, et al. Clinical features and outcomes of bloodstream infections caused by New Delhi metallo-\u03b2-lactamase-producing Enterobacterales during a regional outbreak. Open Forum Infect Dis. 2020;7(2): ofaa011.","journal-title":"Open Forum Infect Dis"},{"key":"1528_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101871","volume":"57","author":"S P\u00e9rez-Galera","year":"2023","unstructured":"P\u00e9rez-Galera S, Bravo-Ferrer JM, Paniagua M, Kostyanev T, de Kraker MEA, Feifel J, et al. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA). eClin Med. 2023;57: 101871. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101871.","journal-title":"eClin Med"},{"issue":"12","key":"1528_CR12","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/cid\/ciad100","volume":"76","author":"M Falcone","year":"2023","unstructured":"Falcone M, Tiseo G, Carbonara S, Marino A, Di Caprio G, Carretta A, et al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram-negative bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis. 2023;76(12):2059\u201369. https:\/\/doi.org\/10.1093\/cid\/ciad100.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1528_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106430","volume":"58","author":"C Zhu","year":"2021","unstructured":"Zhu C, Li C, Lai CKC, Ng R, Chau KY, Wong KT, et al. Longitudinal genomic characterization of carbapenemase-producing Enterobacteriaceae (CPE) reveals changing pattern of CPE isolated in Hong Kong hospitals. Int J Antimicrob Agents. 2021;58(5): 106430. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106430.","journal-title":"Int J Antimicrob Agents"},{"key":"1528_CR14","unstructured":"European Centre for Disease Prevention and Control. Rapid risk assessment: carbapenem-resistant Enterobacteriaceae: first update. 2018. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/RRA-Enterobacteriaceae-Carbapenems-European-Union-countries.pdf. Accessed 4 Aug 2025."},{"issue":"7","key":"1528_CR15","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/jac\/dkad127","volume":"78","author":"AC Gales","year":"2023","unstructured":"Gales AC, Stone G, Sahm DF, Wise MG, Utt E. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017\u20132019. J Antimicrob Chemother. 2023;78(7):1606\u201315. https:\/\/doi.org\/10.1093\/jac\/dkad127.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1528_CR16","volume":"25","author":"L Tavoschi","year":"2020","unstructured":"Tavoschi L, Forni S, Porretta A, Righi L, Pieralli F, Menichetti F, et al. Prolonged outbreak of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019. Euro Surveil. 2020;25(6): 2000085.","journal-title":"Euro Surveil"},{"key":"1528_CR17","unstructured":"Iaachini S, Fadda G, Monaco M, Errico G, Del Grosso M, Giufre M, et al. CRE: sorveglianza nazionale delle batteriemie da enterobatteri resistenti ai carbapenemi. Dati. 2023. https:\/\/www.epicentro.iss.it\/antibiotico-resistenza\/cpe\/RIS-4_2024.pdf. Accessed 27 May 2025."},{"key":"1528_CR18","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.2147\/idr.S341664","volume":"14","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Xiao T, Wang Y, Yang K, Zhou Y, Luo Q, et al. Socioeconomic burden of bloodstream infections caused by carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2021;14:5385\u201393. https:\/\/doi.org\/10.2147\/idr.S341664.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"1528_CR19","doi-asserted-by":"publisher","first-page":"48.e9","DOI":"10.1016\/j.cmi.2016.09.003","volume":"23","author":"SM Bartsch","year":"2017","unstructured":"Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 2017;23(1):48.e9-16. https:\/\/doi.org\/10.1016\/j.cmi.2016.09.003.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"1528_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1089\/sur.2011.039","volume":"15","author":"JA Claridge","year":"2014","unstructured":"Claridge JA, Banerjee A, Kelly KB, Leukhardt WH, Carter JW, Haridas M, et al. Bacterial species-specific hospital mortality rate for intra-abdominal infections. Surg Infect (Larchmt). 2014;15(3):194\u20139. https:\/\/doi.org\/10.1089\/sur.2011.039.","journal-title":"Surg Infect (Larchmt)"},{"key":"1528_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13756-019-0652-x","volume":"8","author":"T Kongnakorn","year":"2019","unstructured":"Kongnakorn T, Eckmann C, Bassetti M, Tichy E, Di Virgilio R, Baillon-Plot N, et al. Cost-effectiveness analysis comparing ceftazidime\/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane\/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). Antimicrob Resist Infect Control. 2019;8:204. https:\/\/doi.org\/10.1186\/s13756-019-0652-x.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"1528_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac064","volume":"4","author":"M Falcone","year":"2022","unstructured":"Falcone M, Suardi LR, Tiseo G, Galfo V, Occhineri S, Verdenelli S, et al. Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study). JAC Antimicrob Resist. 2022;4(3): dlac064.","journal-title":"JAC Antimicrob Resist"},{"key":"1528_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jhin.2023.07.021","volume":"140","author":"M Barchitta","year":"2023","unstructured":"Barchitta M, Maugeri A, Favara G, Lio RMS, La Rosa MC, D\u2019Ancona F, et al. The intertwining of healthcare-associated infections and COVID-19 in Italian intensive care units: an analysis of the SPIN-UTI project from 2006 to 2021. J Hosp Infect. 2023;140:124\u201331. https:\/\/doi.org\/10.1016\/j.jhin.2023.07.021.","journal-title":"J Hosp Infect"},{"issue":"5","key":"1528_CR24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/cid\/ciad725","volume":"78","author":"M Falcone","year":"2023","unstructured":"Falcone M, Giordano C, Leonildi A, Galfo V, Lepore A, Suardi LR, et al. Clinical features and outcomes of infections caused by metallo-\u03b2-lactamase-producing Enterobacterales: a 3-year prospective study from an endemic area. Clin Infect Dis. 2023;78(5):1111\u20139. https:\/\/doi.org\/10.1093\/cid\/ciad725.","journal-title":"Clin Infect Dis"},{"key":"1528_CR25","unstructured":"European Medicines Agency. Emblaveo: summary of product characteristics. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240422162367\/anx_162367_en.pdf. Accessed 30 Jul 2024."},{"issue":"2","key":"1528_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/s1473-3099(24)00499-7","volume":"25","author":"Y Carmeli","year":"2025","unstructured":"Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J, et al. Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect Dis. 2025;25(2):218\u201330. https:\/\/doi.org\/10.1016\/s1473-3099(24)00499-7.","journal-title":"Lancet Infect Dis"},{"key":"1528_CR27","unstructured":"ClinicalTrials.gov. Efficacy, safety, and tolerability of ATM-AVI in the treatment of serious infection due to MBL-producing Gram-negative bacteria. https:\/\/clinicaltrials.gov\/study\/NCT03580044. Accessed 4 Aug 2025."},{"issue":"2","key":"1528_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106611","volume":"60","author":"G Tiseo","year":"2022","unstructured":"Tiseo G, Brigante G, Giacobbe DR, Maraolo AE, Gona F, Falcone M, et al. Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). Int J Antimicrob Agents. 2022;60(2): 106611. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106611.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"1528_CR29","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales. Clin Infect Dis. 2021;72(11):1871\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa586.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1528_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2627-y","volume":"23","author":"JM Cisneros","year":"2019","unstructured":"Cisneros JM, Rosso-Fern\u00e1ndez CM, Roca-Oporto C, De Pascale G, Jim\u00e9nez-Jorge S, Fern\u00e1ndez-Hinojosa E, et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (magic bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care. 2019;23(1): 383. https:\/\/doi.org\/10.1186\/s13054-019-2627-y.","journal-title":"Crit Care"},{"key":"1528_CR31","unstructured":"European Medicines Agency. Tygacil: summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tygacil-epar-product-information_en.pdf. Accessed 21 May 2025."},{"key":"1528_CR32","unstructured":"European Medicines Agency. Fetcroja: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fetcroja-epar-product-information_en.pdf. Accessed 4 Aug 2025."},{"issue":"1","key":"1528_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2110-5820-1-14","volume":"1","author":"H Spapen","year":"2011","unstructured":"Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honor\u00e9 PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):14. https:\/\/doi.org\/10.1186\/2110-5820-1-14.","journal-title":"Ann Intensive Care"},{"key":"1528_CR34","unstructured":"European Medicines Agency. Emblaveo: public assessment report. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/emblaveo-epar-public-assessment-report_en.pdf. Accessed 21 May 2025."},{"key":"1528_CR35","unstructured":"Agenzia Italiana del Farmaco (AIFA). Targeted therapy of infections caused by multi\u2011drug resistant Gram negative bacteria in hospitalized patients. 2022. www.aifa.gov.it\/documents\/20142\/1787183\/AIFA-OPERA_Raccomandazioni_pazienti_ospedalizzati.pdf. Accessed 30 Jul 2024."},{"issue":"9","key":"1528_CR36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","volume":"13","author":"DR Giacobbe","year":"2024","unstructured":"Giacobbe DR, Labate L, Russo Artimagnella C, Marelli C, Signori A, Di Pilato C, et al. Use of cefiderocol in adult patients: descriptive analysis from a prospective, multicenter, cohort study. Infect Dis Ther. 2024;13(9):1929\u201348. https:\/\/doi.org\/10.1007\/s40121-024-01016-y.","journal-title":"Infect Dis Ther"},{"issue":"43","key":"1528_CR37","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2022.27.43.2200795","volume":"27","author":"M Coppi","year":"2022","unstructured":"Coppi M, Antonelli A, Niccolai C, Bartolini A, Bartolini L, Grazzini M, et al. Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022. Euro Surveill. 2022;27(43): 2200795. https:\/\/doi.org\/10.2807\/1560-7917.Es.2022.27.43.2200795.","journal-title":"Euro Surveill"},{"issue":"3","key":"1528_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.cmi.2023.11.005","volume":"30","author":"C Tascini","year":"2024","unstructured":"Tascini C, Coppi M, Antonelli A, Niccolai C, Bartolini A, Pecori D, et al. In vivo evolution to high-level cefiderocol resistance of NDM-1-producing Klebsiella pneumoniae, followed by intra-hospital cross-transmission. Clin Microbiol Infect. 2024;30(3):398\u2013400. https:\/\/doi.org\/10.1016\/j.cmi.2023.11.005.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1528_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00228-023-03609-x","volume":"80","author":"S Das","year":"2024","unstructured":"Das S, Riccobene T, Carrothers TJ, Wright JG, MacPherson M, Cristinacce A, et al. Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for phase IIa and phase III evaluation. Eur J Clin Pharmacol. 2024;80(4):529\u201343. https:\/\/doi.org\/10.1007\/s00228-023-03609-x.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1528_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10198-021-01375-0","volume":"23","author":"I Vlachaki","year":"2022","unstructured":"Vlachaki I, Zinzi D, Falla E, Mantopoulos T, Guy H, Jandu J, et al. Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK. Eur J Health Econ. 2022;23(3):537\u201349. https:\/\/doi.org\/10.1007\/s10198-021-01375-0.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"1528_CR41","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s40121-022-00607-x","volume":"11","author":"J Yang","year":"2022","unstructured":"Yang J, Naik J, Massello M, Ralph L, Dillon RJ. Cost-effectiveness of imipenem\/cilastatin\/relebactam compared with colistin in treatment of Gram-negative infections caused by carbapenem-non-susceptible organisms. Infect Dis Ther. 2022;11(4):1443\u201357. https:\/\/doi.org\/10.1007\/s40121-022-00607-x.","journal-title":"Infect Dis Ther"},{"key":"1528_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1118307","author":"W Kong","year":"2023","unstructured":"Kong W, Yang X, Shu Y, Li S, Song B, Yang K. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1118307.","journal-title":"Front Public Health"},{"issue":"2","key":"1528_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ijantimicag.2016.07.023","volume":"49","author":"KZ Vardakas","year":"2017","unstructured":"Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49(2):233\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.07.023.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1528_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14787210.2024.2307912","volume":"22","author":"N Gupta","year":"2024","unstructured":"Gupta N, Boodman C, Prayag P, Manesh A, Kumar TP. Ceftazidime-avibactam and aztreonam combination for carbapenem-resistant Enterobacterales bloodstream infections with presumed metallo-\u03b2-lactamase production: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2024;22(4):203\u20139. https:\/\/doi.org\/10.1080\/14787210.2024.2307912.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"1528_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054971","volume":"11","author":"R Zhou","year":"2021","unstructured":"Zhou R, Fang X, Zhang J, Zheng X, Shangguan S, Chen S, et al. Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis. BMJ Open. 2021;11(12): e054971. https:\/\/doi.org\/10.1136\/bmjopen-2021-054971.","journal-title":"BMJ Open"},{"issue":"7","key":"1528_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy150","volume":"5","author":"A Martin","year":"2018","unstructured":"Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis. 2018;5(7): ofy150. https:\/\/doi.org\/10.1093\/ofid\/ofy150.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1528_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050694","volume":"11","author":"Y Lashari","year":"2022","unstructured":"Lashari Y, Rochmanti M, Purba AKR, Notobroto HB, Sarassari R, Kuntaman K. The economic impact of carbapenem resistant-non lactose fermenter and Enterobacteriaceae infections on hospital costs in Dr. Soetomo General Academic Hospital Surabaya, Indonesia. Antibiotics (Basel). 2022;11(5): 694. https:\/\/doi.org\/10.3390\/antibiotics11050694.","journal-title":"Antibiotics (Basel)"},{"issue":"12","key":"1528_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001311","volume":"2","author":"Y Cai","year":"2022","unstructured":"Cai Y, Hoo GSR, Lee W, Tan BH, Yoong J, Teo YY, et al. Estimating the economic cost of carbapenem resistant Enterobacterales healthcare associated infections in Singapore acute-care hospitals. PLoS Glob Public Health. 2022;2(12): e0001311. https:\/\/doi.org\/10.1371\/journal.pgph.0001311.","journal-title":"PLoS Glob Public Health"},{"issue":"5","key":"1528_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285170","volume":"18","author":"AN Poudel","year":"2023","unstructured":"Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, et al. The economic burden of antibiotic resistance: a systematic review and meta-analysis. PLoS\u00a0One. 2023;18(5): e0285170. https:\/\/doi.org\/10.1371\/journal.pone.0285170.","journal-title":"PLoS\u00a0One"},{"issue":"3","key":"1528_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/0272989X13519863","volume":"34","author":"JJ Barendregt","year":"2014","unstructured":"Barendregt JJ. The life table method of half cycle correction: getting it right. Med Decis Mak. 2014;34(3):283\u20135. https:\/\/doi.org\/10.1177\/0272989X13519863.","journal-title":"Med Decis Mak"},{"issue":"5","key":"1528_CR51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1197\/j.aem.2005.11.084","volume":"13","author":"SB Murray","year":"2006","unstructured":"Murray SB, Bates DW, Ngo L, Ufberg JW, Shapiro NI. Charlson index is associated with one-year mortality in emergency department patients with suspected infection. Acad Emerg Med. 2006;13(5):530\u20136. https:\/\/doi.org\/10.1197\/j.aem.2005.11.084.","journal-title":"Acad Emerg Med"},{"issue":"1","key":"1528_CR52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/009286150103500122","volume":"35","author":"S Capri","year":"2001","unstructured":"Capri S, Ceci A, Terranova L, Merlo F, Mantovani L, The Members of the Italian Group for Pharmacoeconomic Studies. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J. 2001;35(1):189\u2013201. https:\/\/doi.org\/10.1177\/009286150103500122.","journal-title":"Drug Inf J"},{"key":"1528_CR53","unstructured":"Rinaldi M, De Pascale G, Cortegiani A, Tanzarella ES, Milazzo M, Romana Fasano F, et al. Incidence risk of hospital-acquired infections due to carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa spp. in patients treated in ICUs in Italy. Presented at the ESCMID Global Congress; 28 April 2024; Barcelona: poster no. P0848."},{"key":"1528_CR54","unstructured":"World Health Organization (WHO). Antimicrobial resistance. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance. Accessed 19 Sep 2023."},{"key":"1528_CR55","unstructured":"World Health Organization. Antimicrobial resistance: global report on surveillance. https:\/\/www.who.int\/publications\/i\/item\/9789241564748. Accessed 19 Sep 2023."},{"issue":"Suppl_1","key":"1528_CR56","doi-asserted-by":"publisher","first-page":"ofae631.312","DOI":"10.1093\/ofid\/ofae631.312","volume":"12","author":"H Leister-Tebbe","year":"2025","unstructured":"Leister-Tebbe H, Yuan J, Carmeli Y, Cisneros J-M, Daikos GL, Paul M, et al. P-105. Aztreonam-avibactam compared with adjunctive colistin combined with meropenem for the treatment of serious Gram-negative bacterial infections: subgroup analysis of the phase 3 REVISIT study. Open Forum Infect Dis. 2025;12(Suppl_1):ofae631.312. https:\/\/doi.org\/10.1093\/ofid\/ofae631.312.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1528_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9.","journal-title":"Lancet Infect Dis"},{"key":"1528_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jgar.2023.12.027","volume":"36","author":"GM Rossolini","year":"2024","unstructured":"Rossolini GM, Arhin FF, Kantecki M. In vitro activity of aztreonam-avibactam and comparators against metallo-\u03b2-lactamase-producing Enterobacterales from ATLAS global surveillance program, 2016\u20132020. J Glob Antimicrob Resist. 2024;36:123\u201331. https:\/\/doi.org\/10.1016\/j.jgar.2023.12.027.","journal-title":"J Glob Antimicrob Resist"},{"key":"1528_CR59","unstructured":"Pfizer. Emblaveo APACHE score \u22658 subgroup analysis acute renal injury table. Data on file, 2023."},{"issue":"12","key":"1528_CR60","doi-asserted-by":"publisher","first-page":"e00897","DOI":"10.1128\/aac.00897-19","volume":"63","author":"MS Simon","year":"2019","unstructured":"Simon MS, Sfeir MM, Calfee DP, Satlin MJ. Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia. Antimicrob Agents Chemother. 2019;63(12):e00897-e919. https:\/\/doi.org\/10.1128\/aac.00897-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1528_CR61","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1086\/656591","volume":"31","author":"BY Lee","year":"2010","unstructured":"Lee BY, Wiringa AE, Bailey RR, Goyal V, Tsui B, Lewis GJ, et al. The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2010;31(11):1130\u20138. https:\/\/doi.org\/10.1086\/656591.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"1528_CR62","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1097\/ccm.0000000000002484","volume":"45","author":"MD Whittington","year":"2017","unstructured":"Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for methicillin-resistant Staphylococcus aureus prevention in adult ICUs: a cost-effectiveness analysis. Crit Care Med. 2017;45(8):1304\u201310. https:\/\/doi.org\/10.1097\/ccm.0000000000002484.","journal-title":"Crit Care Med"},{"key":"1528_CR63","unstructured":"Hernandez Alava M, Pudney S, Wailoo A. Estimating EQ-5D by age and sex for the UK. https:\/\/www.sheffield.ac.uk\/nice-dsu\/methods-development\/estimating-eq-5d. Accessed 4 Aug 2025."},{"key":"1528_CR64","unstructured":"Italian National Institute of Statistics, Istat. Life tables. 2011. http:\/\/dati.istat.it\/Index.aspx?QueryId=19052&lang=en. Accessed 15 May 2023."},{"key":"1528_CR65","unstructured":"The World Bank. Inflation, consumer prices (annual %): Italy. https:\/\/data.worldbank.org\/indicator\/FP.CPI.TOTL.ZG?locations=IT. Accessed 13 Jul 2023."},{"key":"1528_CR66","unstructured":"European Medicines Agency. Colomycin: summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/1094\/smpc\/print. Accessed 4 Aug 2025."},{"key":"1528_CR67","unstructured":"Archivio Farmadati. https:\/\/www.farmadati.it\/. Accessed 4 Aug 2025."},{"key":"1528_CR68","unstructured":"European Medicines Agency. Zerbaxa: summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003772\/WC500194595.pdf. Accessed 4 Aug 2025."},{"issue":"12","key":"1528_CR69","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40265-024-02102-8","volume":"84","author":"C Hidalgo-Tenorio","year":"2024","unstructured":"Hidalgo-Tenorio C, Bou G, Oliver A, Rodr\u00edguez-Aguirregabiria M, Salavert M, Mart\u00ednez-Mart\u00ednez L. The challenge of treating infections caused by metallo-\u03b2-lactamase-producing Gram-negative bacteria: a narrative review. Drugs. 2024;84(12):1519\u201339. https:\/\/doi.org\/10.1007\/s40265-024-02102-8.","journal-title":"Drugs"},{"issue":"2","key":"1528_CR70","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40620-016-0291-8","volume":"30","author":"A Roggeri","year":"2017","unstructured":"Roggeri A, Roggeri DP, Zocchetti C, Bersani M, Conte F. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. J Nephrol. 2017;30(2):263\u20139. https:\/\/doi.org\/10.1007\/s40620-016-0291-8.","journal-title":"J Nephrol"},{"key":"1528_CR71","unstructured":"Pfizer. INCREASE-IT. Data on file, 2024."},{"key":"1528_CR72","unstructured":"Falcone M, Gheorghe M, Kamat S, Little C, Panigrahi SP, Broughton E, et al. Feasibility assessment for indirect treatment comparisons (ITC) of aztreonam-avibactam (ATM-AVI) vs comparators for treating serious infections caused by Enterobacterales, including metallo-beta-lactamase (MBL)-producing pathogens. Presented at ESCMID Global; 11-15 April 2025; Vienna: p. 3591. https:\/\/www.escmid.org\/fileadmin\/escmid\/media\/pdf\/abstract_books\/Abstractbook_Vienna_2025.pdf. Accessed 28 May 2025."},{"issue":"4","key":"1528_CR73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391\u2013400. https:\/\/doi.org\/10.1016\/s1473-3099(18)30099-9.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1528_CR74","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/s1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327. https:\/\/doi.org\/10.1016\/s1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1528_CR75","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.bjae.2023.09.001","volume":"23","author":"M Ippolito","year":"2023","unstructured":"Ippolito M, Cortegiani A. Empirical decision-making for antimicrobial therapy in critically ill patients. BJA Educ. 2023;23(12):480\u20137. https:\/\/doi.org\/10.1016\/j.bjae.2023.09.001.","journal-title":"BJA Educ"},{"issue":"6","key":"1528_CR76","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","volume":"31","author":"G Sangiorgio","year":"2025","unstructured":"Sangiorgio G, Calvo M, Stefani S. Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: a narrative review. Clin Microbiol Infect. 2025;31(6):971\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2024.11.006.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"1528_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad609","volume":"10","author":"N Duffy","year":"2023","unstructured":"Duffy N, Li R, Czaja CA, Johnston H, Janelle SJ, Jacob JT, et al. Trends in incidence of carbapenem-resistant Enterobacterales in 7 US sites, 2016\u20132020. Open Forum Infect Dis. 2023;10(12): ofad609. https:\/\/doi.org\/10.1093\/ofid\/ofad609.","journal-title":"Open Forum Infect Dis"},{"key":"1528_CR78","unstructured":"World Health Organization (WHO). Surveillance of antimicrobial resistance. 2022. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Nov2023-ECDC-WHO-Executive-Summary.pdf. Accessed 21 May 2025."},{"issue":"8","key":"1528_CR79","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/13696998.2017.1333960","volume":"20","author":"V Prabhu","year":"2017","unstructured":"Prabhu V, Foo J, Ahir H, Sarpong E, Merchant S. Cost-effectiveness of ceftolozane\/tazobactam plus metronidazole compared with piperacillin\/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK. J Med Econ. 2017;20(8):840\u20139. https:\/\/doi.org\/10.1080\/13696998.2017.1333960.","journal-title":"J Med Econ"},{"key":"1528_CR80","unstructured":"Quattrocolo F, D\u2019Ambrosio A, Corcione S, Stillo M, Blanco V, Gualano M, et al. Studio di Prevalenza Italiano Sulle Infezioni Correlate All\u2019Assistenza e Sull\u2019uso di Antibiotici Negli Ospedali per Acuti-Protocollo ECDC. Dipartimento Scienze della Salute Pubblica e Pediatriche, Turin: Universit\u00e0 di Torino; 2018"},{"key":"1528_CR81","unstructured":"Pfizer. Length of stay data analysis from the micro-ITT population of the REVISIT trial. Data on file, 2024."},{"issue":"1","key":"1528_CR82","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jval.2011.09.007","volume":"15","author":"SS Tan","year":"2012","unstructured":"Tan SS, Bakker J, Hoogendoorn ME, Kapila A, Martin J, Pezzi A, et al. Direct cost analysis of intensive care unit stay in four European countries: applying a standardized costing methodology. Value Health. 2012;15(1):81\u20136. https:\/\/doi.org\/10.1016\/j.jval.2011.09.007.","journal-title":"Value Health"},{"key":"1528_CR83","unstructured":"Ministero dell\u2019Economia e delle Finanze. Libro verde sulla spesa pubblica. 2007. https:\/\/www.anpo.net\/wp-content\/uploads\/file-manager\/OCSE\/libro_verde_spesa_sanitaria2007.pdf#:~:text=Ministero%20dell%E2%80%99Economia%20e%20delle%20Finanze%20Commissione%20Tecnica%20per,prime%20indicazioni%20Doc.%202007%2F6%20Roma%2C%206%20settembre%202007. Accessed 23 May 2023."},{"key":"1528_CR84","unstructured":"Ministero DElla Salute. Tariffe assistenza specialistica ambulatoriale. https:\/\/www.salute.gov.it\/imgs\/C_17_pagineAree_1767_listaFile_itemName_0_file.pdf. Accessed Feb 2024."},{"key":"1528_CR85","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/ceor.S98226","volume":"8","author":"A Mozzi","year":"2016","unstructured":"Mozzi A, Meregaglia M, Lazzaro C, Tornatore V, Belfiglio M, Fattore G. A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. Clinicoecon Outcomes Res. 2016;8:267\u201374. https:\/\/doi.org\/10.2147\/ceor.S98226.","journal-title":"Clinicoecon Outcomes Res."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01528-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01528-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01528-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:00:44Z","timestamp":1762772444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01528-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":85,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01528-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"27 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Pfizer. Work by Source Health Economics was funded by Pfizer. Editorial and medical writing assistance was provided by Kelly O\u2019Toole and Phillipa White, of Source Health Economics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Maria Gheorge, Roberto Di Virgilio, Maria Alejandra Vidal Pereira and Michal Kantecki are employees of Pfizer and hold stock options. Fionn Woodcock and Xiyu Bao are employees of Source Health Economics, a consultancy company that received funding from Pfizer to provide health economic and writing services for this project. Marco Falcone has received research grants from MSD, Gilead, and Menarini and participated in advisory boards or received speaker fees from Pfizer, Menarini, Thermo Fisher, Mundipharma and Shionogi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article as supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors: study concept and design, acquisition of data and critical revision of the manuscript. All authors have given approval to the final version of the manuscript. MG: analysis and interpretation of data, drafting of the manuscript, obtained funding, administrative, technical, or material support, and study supervision. XB and FW: analysis and interpretation of data, drafting of the manuscript and statistical analysis.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}